PGAM
TRIL

Princeton Global Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Princeton Global Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000
Closed -$10K – 561
2021
Q2 		$10K Hold
1,000
– – ﹤0.01% 417
2021
Q1 		$11K Hold
1,000
– – ﹤0.01% 375
2020
Q4 		$15K Hold
1,000
– – 0.01% 361
2020
Q3 		$14K Hold
1,000
– – 0.01% 329
2020
Q2 		$8K Hold
1,000
– – ﹤0.01% 434
2020
Q1 		$4K Buy
+1,000
New +$3.78K ﹤0.01% 445

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Princeton Global Asset Management's TRIL Position: Q3 2021 in Review

Princeton Global Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 1,000 shares — an estimated $10K sold.

Princeton Global Asset Management first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $15K in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Princeton Global Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Princeton Global Asset Management sold 1,000 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $10K.
  • Princeton Global Asset Management first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
  • Princeton Global Asset Management's Trillium Therapeutics Inc. position peaked at $15K in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Princeton Global Asset Management's 13F filing for Q3 2021, filed 3 Nov 2021.